tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Celldex price target lowered to $42 from $50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Celldex (CLDX) to $42 from $50 and keeps a Buy rating on the shares. The company announced mixed topline results from its Phase 2 trial assessing barzolvolimab in eosinophilic esophagitis, the analyst tells investors in a research note. The firm removing eosinophilic esophagitis from its barzolvolimab projected indications.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1